Genocea Biosciences (GNCA) Tops Q2 EPS by 1c

Genocea Biosciences (NASDAQ: GNCA) reported Q2 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).

“We continue to advance our clinical programs for patients living with cancer,” said Chip Clark, President and Chief Executive Officer, Genocea. “I am pleased by our ability to remain on track during these uncertain times, meeting our highest priority milestones and working to deliver on the promise of developing effective immunotherapies through our unique and differentiated approach.”

Guidance
Genocea expects that its existing cash and cash equivalents inclusive of the private placement proceeds are sufficient to support its operations to mid-2022.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c